Fully Funded DKFZ PhD Position 2026 in Translational Cancer Biology at LMU Munich
The German Cancer Research Center offers a fully funded three-year doctoral position focusing on translational cancer biology and small cell lung cancer at LMU Munich. Successful candidates will join the DKFZ International PhD Program with an expected start date of November 2026.
Overview
The German Cancer Research Center (DKFZ) is accepting applications for a fully funded PhD position in Translational Cancer Biology at the German Cancer Consortium (DKTK) partner site in Munich, Germany. Based at LMU Klinikum Großhadern, the three-year doctoral project investigates the molecular mechanisms driving the progression, metastasis, and therapy resistance of small cell lung cancer.
The successful candidate will combine experimental cancer biology with functional genomics, advanced disease models, and computational analysis of large-scale sequencing data. The selected researcher will also join the DKFZ International PhD Program to receive structured doctoral training and professional development.
Eligibility
- Hold a master’s degree in molecular medicine, human biology, biochemistry, biology, molecular biology, biomedical sciences, cancer biology, biotechnology, or another closely related life-science discipline.
- Possess practical laboratory experience in molecular biology and mammalian cell culture.
- Demonstrate a strong interest in translational cancer research, gene regulation, and interdisciplinary collaboration.
- Show proficiency in written and spoken English.
Applicants must meet the following academic and practical criteria:
How to Apply
Applications must be submitted through the official DKFZ online recruitment system. Email or postal applications are not accepted.
Candidates should prepare documentation demonstrating their master’s qualification, laboratory skills, research motivation, and relevant experience. Additional submission guidelines and portal details can be found on the application page.
Deadline
The application deadline is 11 August 2026.